APCU25OS1 Hospital Pakar universiti SAINS Malaysia TAVI registry

Introduction Transcatheter aortic valve implantation (TAVI) is now a well-established alternative to surgical aortic valve replacement for severe symptomatic aortic stenosis, particularly in elderly and high-risk patients. Contemporary registries report 30-day mortality of 2–5% and device success >95%. We describe our centre’s early experience.Methods Retrospective analysis of 17 consecutive patients undergoing TAVI between 2020–2025 was performed. Clinical, procedural, echocardiographic, and survival data were collected.Results Mean age was 76 years (61–87); 94% presented in NYHA class III. Common comorbidities included hypertension (65%), diabetes (47%), CKD (29%), ESRD on dialysis (12%), atrial fibrillation (18%), and CAD (53%, prior PCI in 35%). Device success was 100%. Mild PVL occurred in 18%; none had moderate/severe PVL. Complications included two cases of complete heart block requiring pacemaker implantation, one peri-procedural cardiac arrest (resuscitated), and one post-procedural infection. Aortic valve gradients improved from 46 mmHg at baseline to 12 mmHg at 12 months, with preserved LVEF. One patient (6%) died within 30 days. At latest follow-up, 14 of 17 (82%) were alive. Causes of death included both cardiac and non-cardiac aetiologies.Discussion Our study demonstrates that early survival following TAVI at our centre compares favourably with international benchmarks. While one early death (6%) occurred, this is consistent with 30-day mortality rates reported in multicentre registries (2–5%). Overall survival at follow-up was 82%, reflecting both the effectiveness of TAVI and the high comorbidity burden of this elderly cohort.Conclusion Our early institutional experience demonstrates excellent procedural success, low complication rates, and hemodynamic improvement. Thirty-day mortality (6%) was within expected benchmarks, with 82% survival at follow-up. Larger cohorts and longer follow-up are needed to evaluate durability and optimize post-TAVI care.